NasdaqGS - Delayed Quote USD

Molecular Partners AG (MOLN)

Compare
4.8700 -0.1100 (-2.21%)
At close: October 18 at 4:00 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for MOLN

Recent News: MOLN

View More
Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting

Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting
Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a 212Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024

Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a 212Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024
Molecular Partners Reports H1 2024 Corporate Highlights and Financials

Molecular Partners Reports H1 2024 Corporate Highlights and Financials
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit

Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit
Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024

Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024
Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024

Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024
Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024

Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024
Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program

Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program
Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data?Supporting MP0533’s Proposed Mechanism of Action

Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data?Supporting MP0533’s Proposed Mechanism of Action
Life Science Cares Launches in Switzerland

Life Science Cares Launches in Switzerland
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting

Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting
View More

Related Tickers